Jonben Svoboda, MD
Endocrinology, Diabetes & Metabolism · Springfield, MONPI 1831198993
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $128,359 of the $141,568 with a category attached, or 90.7%. Novo Nordisk accounts for 63.8% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $55,254 and has fallen 98.9% since, to $588 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 492 payments — averaging $287.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$90K
- Johnson & Johnson$37K
- AstraZeneca$10K
- Abbott$721
- Amgen$603
- Dexcom, Inc.$498
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$128,35991%
- Travel & lodging$5,7394%
- Food & beverage$7,4605%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 134 | $90,290 |
| Johnson & Johnson | 59 | $37,099 |
| AstraZeneca | 31 | $9,866 |
| Abbott | 42 | $721 |
| Amgen | 33 | $603 |
| Dexcom, Inc. | 42 | $498 |
| Boehringer Ingelheim | 23 | $383 |
| Sanofi-aventis U.S. LLC | 25 | $303 |
| Pfizer | 19 | $264 |
| Lilly USA, LLC | 15 | $224 |
| Insulet Corporation | 4 | $210 |
| Antares Pharma, Inc. | 7 | $99 |
| Tandem Diabetes Care, Inc. | 2 | $90 |
| Radius Health, Inc. | 4 | $79 |
| Novartis | 5 | $76 |
| Amarin Pharma, Inc. | 3 | $63 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Shire North American Group Inc | 5 | $59 |
| AbbVie | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Bayer | 3 | $48 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Merck | 3 | $43 |
| Eisai Inc. | 2 | $41 |
| Corcept Therapeutics | 2 | $34 |
| Medtronic | 2 | $30 |
| Valeritas, Inc. | 2 | $30 |
| Aegerion Pharmaceuticals, Inc. | 2 | $24 |
| Intuity Medical Inc | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| Cequr Corporation | 1 | $23 |
| BETA Bionics, Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
| GSK | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,568 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $128,552 |
| FarxigaDapagliflozin Propanediol | 74 | $61,956 |
| JardianceEmpagliflozin | 73 | $59,215 |
| TrulicityDulaglutide | 28 | $32,385 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $26,518 |
| InvokanaCanagliflozin | 27 | $25,983 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $21,117 |
| MounjaroTirzepatide | 16 | $16,587 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $14,760 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $14,230 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $11,251 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $9,757 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $9,737 |
| SynthroidLevothyroxine Sodium | 123 | $8,956 |
| Novolog FlexpenInsulin Aspart | 39 | $8,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $90,290 | $128,552102 claims |
| AstraZenecaFarxiga | $9,866 | $61,95674 claims |
| Boehringer IngelheimJardiance | $383 | $59,21573 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $224 | $52,64073 claims |
| Johnson & JohnsonInvokana | $37,099 | $25,98327 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $303 | $22,33135 claims |
| AbbVieSynthroid | $56 | $8,956123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Springfield
- Ralph DudaSpringfield$644K
- James BonucchiSpringfield$128K
- Ana Rivas MejiaSpringfield$5K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Christopher CaseJefferson City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.